Skip to main content

Advertisement

SpringerLink
Log in

Infliximab Treatment for Ocular and Extraocular Manifestations of Behçet's Disease

  • CLINICAL INVESTIGATION
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To assess the efficacy and safety of infliximab in the treatment of sight-threatening uveitis and extraocular manifestations in patients with Behçet's disease.

Methods

Twelve patients with Behçet's disease and uveitis were treated with infliximab after unsuccessful therapy with other immunosuppressive drugs. The main outcome measures were as follows: the number of uveitis relapses, the number of Behçet's disease-related extraocular lesions, and the amount of corticosteroids administered during the treatment as well as during an equal prior period of time while the patients were on other immunosuppressive agents. Visual acuity was recorded at the beginning of infliximab therapy and at the end of follow-up, and was defined as stable if it did not change from baseline, increased if it showed at least one line of improvement from baseline, and decreased if it showed at least a one line decrease from baseline.

Results

During an average follow-up of 16.67 ± 7.63 months (median, 15 months), 11 patients (91.6%) showed a reduction in the number of ocular relapses (relapse/month, from 0.35 ± 0.17 to 0.12 ± 0.17, P < 0.001). All of the patients (n = 11) who were taking corticosteroids before infliximab were able to reduce the amount of corticosteroids taken daily during infliximab treatment (from 24.33 ± 10.84 mg/prednisone per day to 8.97 ± 6.81 mg/prednisone per day, P < 0.001), and all presented with a reduced onset of extraocular manifestations of Behçet's disease (mean total number, from 2.83 ± 3.61 to 1.51 ± 2.35, P = 0.039). One patient, who had to stop treatment 2 months after starting because of the onset of pulmonary tuberculosis, showed the same number of relapses during infliximab treatment but was able to reduce the mean daily corticosteroid dose. Visual acuity increased by one or more lines in three eyes (12.5%) and remained unchanged in 87.5% of the eyes. Infliximab-related side effects appeared in four patients (33.3%).

Conclusions

Infliximab was effective in the treatment of uveitis in these Behçet's disease patients, significantly reducing the number of ocular relapses and making possible a significant reduction in the daily dose of corticosteroids administered. Extraocular manifestations of Behçet's disease were also controlled by infliximab. Nevertheless, side effects were not uncommon, and an extensive study of systemic conditions before infliximab administration had to be carried out to exclude systemic infection, particularly prior tuberculosis. Jpn J Ophthalmol 2007;51:191–196 © Japanese Ophthalmological Society 2007

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. H Behçet (1937) ArticleTitleÜber rezidivierende Aphthose, durch ein Virus verurusachte Geschwüre in Mund, am Auge und an den Genitalien Dematol Wochenschr 105 1152

    Google Scholar 

  2. P Pivetti-Pezzi V Gasparri P De Liso G Catarinelli (1985) ArticleTitlePrognosis in Behçet's disease Ann Ophthalmol 17 20–25 Occurrence Handle3977213 Occurrence Handle1:STN:280:DyaL2M7kslWqug%3D%3D

    PubMed  CAS  Google Scholar 

  3. SM Whitcup EC Salvo SuffixJr RB Nussenblatt (1994) ArticleTitleCombined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease Am J Ophthalmol 118 39–45 Occurrence Handle8023874 Occurrence Handle1:STN:280:DyaK2c3psFKhsw%3D%3D

    PubMed  CAS  Google Scholar 

  4. VG Kaklamani G Vaiopoulos PG Kaklamanis (1998) ArticleTitleBehçet's disease Semin Arthritis Rheum 27 197–217 Occurrence Handle9514126 Occurrence Handle10.1016/S0049-0172(98)80001-2 Occurrence Handle1:STN:280:DyaK1c7ntlSmuw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  5. SR Boyd S Young S Lightman (2001) ArticleTitleImmunopathology of the noninfectious posterior and intermediate uveitis Surv Ophthalmol 46 209–233 Occurrence Handle11738429 Occurrence Handle10.1016/S0039-6257(01)00275-2 Occurrence Handle1:STN:280:DC%2BD3Mnptlejug%3D%3D

    Article  PubMed  CAS  Google Scholar 

  6. B Turan H Gallati H Erdi A Gurler BA Michel PM Viligger (1997) ArticleTitleSystemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: soluble TNFR-75 as a biological marker of disease activity J Rheumatol 24 128–132 Occurrence Handle9002023 Occurrence Handle1:STN:280:DyaK2s7lsFejuw%3D%3D

    PubMed  CAS  Google Scholar 

  7. M Santos Lacomba C Marcos Martin JM Gallardo Gallera et al. (2001) ArticleTitleAqueous humor and serum tumor necrosis factor-alpha in clinical uveitis Ophthalmic Res 33 251–255 Occurrence Handle11586057 Occurrence Handle10.1159/000055677 Occurrence Handle1:STN:280:DC%2BD3MrjvFelug%3D%3D

    Article  PubMed  CAS  Google Scholar 

  8. H Chronopoulou V Tzavara N Oikonomopoulos et al. (2001) ArticleTitleHigh levels of TNF-α in the aqueous humor in patients suffering from Adamantiades-Behçet's disease: preliminary results Invest Ophthalmol Vis Sci 42 IssueIDSuppl 4 S708

    Google Scholar 

  9. PP Sfikakis PG Theodossiadis CG Katsiari P Kaklamanis NN Markomichleakis (2001) ArticleTitleEffect of infliximab on sight-threatening panuveitis in Behçet's disease Lancet 358 295–296 Occurrence Handle11498218 Occurrence Handle10.1016/S0140-6736(01)05497-6 Occurrence Handle1:CAS:528:DC%2BD3MXlslCjsLg%3D

    Article  PubMed  CAS  Google Scholar 

  10. S Munoz-Fernandez V Hidalgo J Fernandez-Melon J Schlinker Martin-Mola (2001) ArticleTitleEffect of infliximab on threatening panuveitis in Behçet's disease Lancet 358 1644 Occurrence Handle11716917 Occurrence Handle10.1016/S0140-6736(01)06677-6 Occurrence Handle1:STN:280:DC%2BD3MnntFKqtQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  11. PP Sfikakis (2002) ArticleTitleBehçet's disease: a new target for anti-tumor necrosis factor treatment Ann Rheum Dis 61 IssueIDSuppl II ii51–ii53 Occurrence Handle12379622

    PubMed  Google Scholar 

  12. G Triolo M Vadalà A Accardo-Palumbo et al. (2002) ArticleTitleAnti-tumor necrosis factor monoclonal antibody treatment for ocular Behçet's disease Ann Rheum Dis 61 560–561 Occurrence Handle12006336 Occurrence Handle10.1136/ard.61.6.560 Occurrence Handle1:STN:280:DC%2BD383ms1Cquw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  13. M Andreu J Ramanoelina F Fajnkuchen et al. (2002) ArticleTitleTraitment de la maladie de Behçet sèvére par un anti-TNFα: l'infliximab Ann Med Interne 153 414–415

    Google Scholar 

  14. A Joseph D Raj HS Dua PT Powell PC Lanyon RJ Powell (2003) ArticleTitleInfliximab in the treatment of refractory posterior uveitis Ophthalmology 110 1449–1453 Occurrence Handle12867408 Occurrence Handle10.1016/S0161-6420(03)00406-8

    Article  PubMed  Google Scholar 

  15. S Ohno S Nakamura S Hori et al. (2004) ArticleTitleEfficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis J Rheumatol 31 1362–1368 Occurrence Handle15229958 Occurrence Handle1:CAS:528:DC%2BD2cXmtlSlt7o%3D

    PubMed  CAS  Google Scholar 

  16. PP Sfikakis PH Kaklamanis A Elezoglou et al. (2004) ArticleTitleInfliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet's disease Ann Intern Med 140 404–406 Occurrence Handle14996689 Occurrence Handle1:STN:280:DC%2BD2c7gsFWquw%3D%3D

    PubMed  CAS  Google Scholar 

  17. I Tugal-Tutkun A Mudun M Urgancioglu et al. (2005) ArticleTitleEfficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. An open-label trial Arthritis Rheum 52 2478–2484 Occurrence Handle16052571 Occurrence Handle10.1002/art.21231 Occurrence Handle1:CAS:528:DC%2BD2MXpslGht7s%3D

    Article  PubMed  CAS  Google Scholar 

  18. JM Benitez-del-Castillo JM Martinez-de-la-Casa E Pato-Cotor et al. (2005) ArticleTitleLong-term treatment of refractory posterior uveitis with anti-TNF α (infliximab) Eye 19 841–845 Occurrence Handle15389273 Occurrence Handle10.1038/sj.eye.6701689 Occurrence Handle1:CAS:528:DC%2BD2MXntVWjsrs%3D

    Article  PubMed  CAS  Google Scholar 

  19. EW Lindsted GS Baarsma RWAM Kuijpers PM van Hagen (2005) ArticleTitleAnti-TNFα therapy for sight-threatening uveitis Br J Ophthalmol 89 533–536 Occurrence Handle10.1136/bjo.2003.037192

    Article  Google Scholar 

  20. MJ Elliott RM Maini M Feldmann et al. (1994) ArticleTitleRandomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis Lancet 344 1105–1110 Occurrence Handle7934491 Occurrence Handle10.1016/S0140-6736(94)90628-9 Occurrence Handle1:STN:280:DyaK2M%2FitVWktw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  21. PE Lipsky DMF van der Heijde EW St Claire et al. (2000) ArticleTitleAnti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 1594–1602 Occurrence Handle11096166 Occurrence Handle10.1056/NEJM200011303432202 Occurrence Handle1:CAS:528:DC%2BD3cXovVeltLk%3D

    Article  PubMed  CAS  Google Scholar 

  22. SR Targan SB Hanauer SJ van Deventer InstitutionalAuthorNameCrohn's disease cA2 Study Group et al. (1997) ArticleTitleA short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease N Engl J Med 337 1029–1035 Occurrence Handle9321530 Occurrence Handle10.1056/NEJM199710093371502 Occurrence Handle1:CAS:528:DyaK2sXmvVKjsrs%3D

    Article  PubMed  CAS  Google Scholar 

  23. B Scallon A Cai N Solowski et al. (2002) ArticleTitleBinding and functional comparison of two types of tumor necrosis factor (TNF) antagonist J Pharmacol Exp Ther 301 418–426 Occurrence Handle11961039 Occurrence Handle10.1124/jpet.301.2.418 Occurrence Handle1:CAS:528:DC%2BD38XjtlKjurw%3D

    Article  PubMed  CAS  Google Scholar 

  24. InstitutionalAuthorNameInternational Study Group for Behçet's Disease (1990) ArticleTitleCriteria for diagnosis of Behçet's Disease Lancet 335 1078–1080

    Google Scholar 

  25. K Masuda A Nakajima A Urayama K Nakae M Kogure G Inaba (1989) ArticleTitleDouble-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behçet's disease Lancet 1 1093–1096 Occurrence Handle2566048 Occurrence Handle10.1016/S0140-6736(89)92381-7 Occurrence Handle1:STN:280:DyaL1M3jslGrsg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  26. V Hamuryudan Y Ozyazgan N Hizli et al. (1997) ArticleTitleAzathioprine in Behçet's syndrome: effects on long-term prognosis Arthritis Rheum 40 769–774 Occurrence Handle9125262 Occurrence Handle10.1002/art.1780400425 Occurrence Handle1:CAS:528:DyaK2sXivVehtrs%3D

    Article  PubMed  CAS  Google Scholar 

  27. P Pivetti-Pezzi M Accorinti MP Pirraglia R Priori G Valesini (1997) ArticleTitleInterferon alpha for ocular Behçet's disease Acta Ophthalmologica Scand 75 720–722 Occurrence Handle1:CAS:528:DyaK1cXhslCrs7k%3D Occurrence Handle10.1111/j.1600-0420.1997.tb00638.x

    Article  CAS  Google Scholar 

  28. AA Okada (2000) ArticleTitleDrug therapy in Behçet's disease Ocul Immunol Inflamm 130 774–781

    Google Scholar 

  29. DA Goldstein FA Fontanilla S Kaul O Sain HH Tessler (2002) ArticleTitleLong-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation Ophthalmology 109 370–377 Occurrence Handle11825825 Occurrence Handle10.1016/S0161-6420(01)00942-3

    Article  PubMed  Google Scholar 

  30. I Kotter M Zierhut AK Eckstein et al. (2003) ArticleTitleHuman recombinant interferon alpha 2a for the treatment of Behçet's disease with sight-threatening posterior or panuveitis Br J Ophthalmol 87 423–431 Occurrence Handle12642304 Occurrence Handle10.1136/bjo.87.4.423 Occurrence Handle1:STN:280:DC%2BD3s7lsl2jtw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  31. CC Murphy WH Ayliffe A Booth D Makanjula PA Andrews D Jayne (2004) ArticleTitleTumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis Ophthalmology 111 352–356 Occurrence Handle15019389 Occurrence Handle10.1016/S0161-6420(03)00721-8

    Article  PubMed  Google Scholar 

  32. FT Saulsbury JA Mann (2003) ArticleTitleTreatment with infliximab for a child with Behçet's disease Arthritis Rheum 49 599–600 Occurrence Handle12910569 Occurrence Handle10.1002/art.11204

    Article  PubMed  Google Scholar 

  33. G Licata A Pinto A Tuttolomondo et al. (2003) ArticleTitleAnti-tumor necrosis factor a monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome Ann Rheum Dis 62 280–281 Occurrence Handle12594127 Occurrence Handle10.1136/ard.62.3.280 Occurrence Handle1:STN:280:DC%2BD3s7gtl2hsQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  34. P Charles MJ Elliott D Davis et al. (1999) ArticleTitleRegulation of cytokines, cytokine inhibitors, and acute phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis J Immunol 163 1521–1528 Occurrence Handle10415055 Occurrence Handle1:CAS:528:DyaK1MXkslOgsL0%3D

    PubMed  CAS  Google Scholar 

  35. V Perez-Guijo M Santos-Lacomba M Sanchez-Hernandez et al. (2004) ArticleTitleTumor necrosis factor-alpha levels in aqueous humor and serum from patients with uveitis: the involvement of HLA-B27 Curr Med Res Opin 20 155–157 Occurrence Handle15006008 Occurrence Handle10.1185/030079903125002847 Occurrence Handle1:CAS:528:DC%2BD2cXhslKrsb4%3D

    Article  PubMed  CAS  Google Scholar 

  36. J Keane S Gershon RP Wise et al. (2001) ArticleTitleTuberculosis associated with infliximab, a tumor-necrosis factor alpha-neutralizing agent N Engl J Med 345 1098–1104 Occurrence Handle11596589 Occurrence Handle10.1056/NEJMoa011110 Occurrence Handle1:CAS:528:DC%2BD3MXnsFShsr0%3D

    Article  PubMed  CAS  Google Scholar 

  37. WS Lim RJ Powell ID Johnston (2002) ArticleTitleTuberculosis and treatment with infliximab N Engl J Med 346 623–626 Occurrence Handle11856805 Occurrence Handle10.1056/NEJM200202213460815

    Article  PubMed  Google Scholar 

  38. D Khanna M McMahon DE Furst (2004) ArticleTitleSafety of tumor necrosis factor-α antagonists Drug Safety 27 307–324 Occurrence Handle15061685 Occurrence Handle10.2165/00002018-200427050-00003 Occurrence Handle1:CAS:528:DC%2BD2cXkt1Shurg%3D

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servizio di Immunovirologia Oculare, Dipartimento di Scienze Oftalmologiche, Università degli Studi di Roma “La Sapienza”, Rome, Italy

    Massimo Accorinti, Maria Pia Pirraglia, Maria Pia Paroli & Paola Pivetti-Pezzi

  2. Dipartimento di Reumatologia, Università degli Studi di Roma “La Sapienza”, Rome, Italy

    Roberta Priori & Fabrizio Conti

Authors
  1. Massimo Accorinti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Pia Pirraglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Pia Paroli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberta Priori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fabrizio Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paola Pivetti-Pezzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paola Pivetti-Pezzi.

About this article

Cite this article

Accorinti, M., Pirraglia, M., Paroli, M. et al. Infliximab Treatment for Ocular and Extraocular Manifestations of Behçet's Disease. Jpn J Ophthalmol 51, 191–196 (2007). https://doi.org/10.1007/s10384-006-0425-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-006-0425-y

Key words

Search

Navigation